Author Question: Bacterial protein synthesis inhibitors have selective toxicity because: 1. susceptible strains of ... (Read 101 times)

melina_rosy · **on:** Jul 23, 2018

Bacterial protein synthesis inhibitors have selective toxicity because:

1. susceptible strains of bacteria are affected.
2. biochemical processes are the same.
3. human ribosomes are larger and denser than bacterial ribosomes.
4. antibacterial activity is broad-spectrum.

Question 2

The emergency department nurse anticipates that which clients may be treated with ertapenem (Invanz)?

Standard Text: Select all that apply.
1. College student diagnosed with community-acquired pneumonia
2. Client diagnosed with complicated urinary tract infection (UTI)
3. Diabetic client with an infected toe
4. Young child diagnosed with H. influenzae otitis media
5. Older client diagnosed with community-acquired methicillin-resistant S. aureus (MRSA)

emily12345 · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

Correct Answer: 3
Rationale 1: Susceptible strains of bacteria are targeted by the drug's antibacterial activity.
Rationale 2: Biochemical processes that are the same would be targeted by the drug.
Rationale 3: Human ribosomes are larger and denser than bacterial ribosomes. As a result, human ribosomes are not targeted by the drug's antibacterial activity.
Rationale 4: The spectrum of an antibacterial drug describes the range of bacteria it is effective against.
Global Rationale: Human ribosomes are larger and denser than bacterial ribosomes. As a result, human ribosomes are not targeted by the drug's antibacterial activity. Susceptible strains of bacteria are targeted by the drug's antibacterial activity. Biochemical processes that are the same would be targeted by the drug. The spectrum of an antibacterial drug describes the range of bacteria it is effective against.

Answer to Question 2

Correct Answer: 1,2,3
Rationale 1: Ertapenem (Invanz) is approved for the treatment of community-acquired pneumonia.
Rationale 2: Ertapenem (Invanz) is approved for the treatment of complicated UTI.
Rationale 3: Ertapenem (Invanz) is approved for the treatment of diabetic foot infection.
Rationale 4: Ertapenem (Invanz) is not approved for the treatment of H. influenzae otitis media.
Rationale 5: Ertapenem (Invanz) is not approved for the treatment of MRSA.
Global Rationale: Invanz is approved for the treatment of serious abdominopelvic and skin infections, community-acquired pneumonia, complicated UTIs, and diabetic foot infections without concomitant osteomyelitis.